The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells

D. Yee, R. E. Favoni, R. Lupu, K. J. Cullen, G. S. Lebovic, K. K. Huff, P. D.K. Lee, Y. L. Lee, D. R. Powell, R. B. Dickson, N. Rosen, M. E. Lippman

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


Specific binding proteins are thought to modulate the effects of IGF-I. Previous work has demonstrated that media conditioned by human breast cancer cells contains IGF-I binding activity. Radiolabelled IGF-I incubated with serum-free conditioned media from the breast cancer cell line MDA-MB 231 eluted with an apparent M.W. of 35-40 kDa when analyzed by gel filtration chromatography at pH 7.4. The M.W. of this binding activity corresponded to that of BP-25, a binding protein cloned from the hepatocellular carcinoma cell line HepG2. Two breast cancer cell lines, MDA-MB 231 and Hs578T, were found to express BP-25 RNA. Specific BP-25 radioimmunoassay detected BP-25 production in the conditioned media of these two cell lines. Immunoprecipitation confirmed that metabolically labelled MDA-MB 231 released 30 kDa BP-25 into its medium. This study demonstrates that some breast cancer cells express the IGF-I binding protein, BP-25.

Original languageEnglish (US)
Pages (from-to)38-44
Number of pages7
JournalBiochemical and Biophysical Research Communications
Issue number1
StatePublished - Jan 16 1989
Externally publishedYes

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells'. Together they form a unique fingerprint.

Cite this